Scarica l'app Stockscreener
5.44
3.37%
-0.19
Precedente Chiudi:
$5.63
Aprire:
$5.54
Volume 24 ore:
6,361
Relative Volume:
0.07
Capitalizzazione di mercato:
$87.15M
Reddito:
-
Utile/perdita netta:
$-14.72M
Rapporto P/E:
-1.9223
EPS:
-2.83
Flusso di cassa netto:
$-7.41M
1 W Prestazione:
+2.45%
1M Prestazione:
-9.78%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.4279
$5.79
Intervallo di 1 settimana:
$5.23
$5.79
Portata 52W:
$4.66
$7.00
Alpha Cognition Inc Stock (ACOG) Company Profile
Nome
Alpha Cognition Inc
Settore
Industria
Telefono
(858) 344-4375
Indirizzo
1200-750 W PENDER ST, VANCOUVER
Confronta ACOG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
5.44 | 87.15M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.77 | 129.62B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
666.87 | 72.91B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
604.96 | 36.76B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.76 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.19 | 27.86B | 3.32B | -860.46M | -1.04B | -8.32 |
Alpha Cognition Inc Borsa (ACOG) Ultime notizie
Acetylcholinesterase Inhibitors Market is expected to reach - openPR
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey
Alpha Cognition sets new executive and director compensation By Investing.com - Investing.com Australia
Alpha Cognition sets new executive and director compensation - Investing.com India
Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions - Yahoo Finance
Institutions profited after Alpha Cognition Inc.'s (NASDAQ:ACOG) market cap rose US$12m last week but retail investors profited the most - Simply Wall St
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease - Business Wire
Acetylcholinesterase Inhibitors Market Size, Share, Industry - openPR
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) - Newsfile
Stonegate Capital Partners Initiates Coverage on Alpha Cognition's Innovative Alzheimer's Therapy ZUNVEYL - citybuzz -
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - The Manila Times
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - GlobeNewswire Inc.
Alpha Cognition to delist from Canadian Securities Exchange - MSN
Acetylcholinesterase Inhibitors Market: Industry Growth - openPR
Moves at FDA, NIH - BioCentury
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - BioSpace
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon - Verywell Health
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch - TipRanks
Alpha Cognition Expands Leadership Team Ahead of Landmark Alzheimer's Drug Launch in 2025 - StockTitan
Top Dividend Stocks For Reliable Income In January 2025 - Simply Wall St
Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS - News & Insights
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - JCN Newswire
Alpha Cognition licenses ZUNVEYL in Asia and Oceania By Investing.com - Investing.com Canada
ACOG News Today | Why did Alpha Cognition stock go up today? - MarketBeat
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China - AOL
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - The Manila Times
Alpha Cognition licenses ZUNVEYL in Asia and Oceania - Investing.com India
China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL - TipRanks
Alpha Cognition Lands $44M ZUNVEYL Licensing Deal for Massive Asian Alzheimer's Market - StockTitan
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - Business Wire
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - BioSpace
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Alpha Cognition files to sell 1.45M common shares for holders - MSN
Alpha Cognition announces private sale of equity securities - Investing.com
Alpha Cognition stock hits 52-week low at $5.3 amid market challenges - Investing.com Australia
Alpha Cognition Raises $52.8 Million in Stock Offering - TipRanks
Alpha Cognition Raises $52.8M in Nasdaq IPO, Strengthens Alzheimer's Drug Commercialization Plans - StockTitan
Alpha Cognition Reports Promising Data for Brain Injury Drug - TipRanks
CSE Bulletin: DelistAlpha Cognition Inc. (ACOG) - Newsfile
Alpha Cognition Announces Partial Exercise of Over-allotment Option - Business Wire
Alpha Cognition Announces Voluntary Delisting from CSE - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment - MSN
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment | 2024-12-11 | Investing News - Stockhouse Publishing
Alpha Cognition Announces Positive Interim Pre-Clinical Data for Alpha-1062 Use in A Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Marketscreener.com
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - BioSpace
About Us - Financial Content
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Inc. announced that it expects to receive $46.149996 million in funding - Marketscreener.com
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com India
Alpha Cognition Inc Azioni (ACOG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alpha Cognition Inc Azioni (ACOG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):